Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.097 AUD | +5.43% | +3.19% | -11.82% |
Apr. 22 | Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data | MT |
Apr. 22 | PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.82% | 270M | - | ||
+1.77% | 42.86B | B | ||
+46.23% | 41.36B | A | ||
+12.24% | 42.74B | B- | ||
-8.83% | 27.68B | C | ||
+7.44% | 25.15B | B- | ||
-23.01% | 18.63B | B | ||
+30.56% | 12.37B | C+ | ||
-1.82% | 11.92B | C+ | ||
+8.35% | 11.21B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PYC Stock
- Ratings PYC Therapeutics Limited